NCT02075840 · OUTCOME

Percentage of Participants With OS Event

A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants · Source last updated 2026-05-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Percentage of Participants
Interval / dispersion: Not reported
Time frame: From randomization until death (up to 10.5 years)

What was measured

Overall survival (OS) was defined as the time from randomization to death from any cause.

Analysis population: ITT population included all randomized participants in the study. Number of participants analyzed is the total participants who were evaluable for this outcome measure.

Groups in this outcome

Alectinib

Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.

Crizotinib

Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Alectinib	152
Crizotinib	151

Reported measurements

Source class 1

Values in Percentage of Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Alectinib	50.0	Not reported	Not reported	Not reported	Not reported
Crizotinib	48.3	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
50.0
group Id
OG001
value
48.3

denoms

counts
group Id
OG000
value
152
group Id
OG001
value
151
units
Participants

description

Overall survival (OS) was defined as the time from randomization to death from any cause.

groups

description
Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
id
OG000
title
Alectinib
description
Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
id
OG001
title
Crizotinib

param Type

NUMBER

population Description

ITT population included all randomized participants in the study. Number of participants analyzed is the total participants who were evaluable for this outcome measure.

reporting Status

POSTED

time Frame

From randomization until death (up to 10.5 years)

title

Percentage of Participants With OS Event

type

SECONDARY

unit Of Measure

Percentage of Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice